LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Molecular Diagnostics Platform Uses Multiplex PCR Technology for Fast Diagnosis of Severe Infectious Diseases

By LabMedica International staff writers
Posted on 20 Apr 2023
Print article
Image: The Unyvero A50 System can process two cartridges independently with full random-access capabilities (Photo courtesy of Curetis)
Image: The Unyvero A50 System can process two cartridges independently with full random-access capabilities (Photo courtesy of Curetis)

In order to improve patient outcomes in cases of bacterial co-infections like severe pneumonia, rapid detection of pathogens and associated resistance markers is crucial to guide appropriate antibiotic treatment. Now, a cutting-edge molecular diagnostic platform can reliably and accurately diagnose severe infectious diseases by using multiplex PCR technology to detect a wide range of microorganisms, antibiotic resistance markers, or toxins from sample-to-answer within 4-5 hours.

Curetis GmbH’s (Holzgerlingen, Germany) Unyvero A50 system is designed to support various applications for diagnosing severe infectious diseases through syndromic testing. The Unyvero A50 system offers five panels to test for Hospitalized Pneumonia (HPN), Blood Stream Infections (BCU), Implant & Tissue Infections (ITI), Intra-Abdominal Infections (IAI), and Urinary Tract Infections (UTI). Unyvero's multiplex diagnostic panels employ a molecular approach using multiplex PCR technology to detect a wide range of clinically relevant microorganisms and antibiotic resistance markers. This allows for the rapid and accurate identification of infectious agents within less than five hours. The ability to concurrently detect various clinically relevant microorganisms and antibiotic resistance in a single test facilitates prompt identification of likely pathogens and more rapid, targeted antibiotic selection.

The Unyvero multiplex diagnostic panels include the Unyvero Hospitalized Pneumonia (HPN) Cartridge, which tests for 38 reportable targets (21 pathogens and 17 resistance genes) within 4-5 hours, enabling targeted syndromic treatment during the critical early hours of infection. The Unyvero panel range also features the Unyvero Implant & Tissue Infection (ITI) Cartridge, which tests for 46 reportable targets (29 pathogens and 17 resistance genes) and delivers results with high sensitivity and specificity within 4-5 hours. This test panel allows physicians to swiftly diagnose infections and determine the most effective treatment.

Additionally, the Unyvero multiplex diagnostic panels include the Unyvero Blood Culture (BCU) Cartridge for positive blood cultures, testing for 50 reportable targets (34 pathogens and 16 resistance genes) with a single sample, delivering results with high sensitivity and specificity within 4-5 hours. Additionally, the panels range features the Unyvero Intra-Abdominal Infection (IAI) Cartridge, which tests for 50 targets (26 pathogens, 2 toxins, and 22 resistance genes) with a 4-5 hour sample-to-answer time. Based on this comprehensive analysis, physicians can promptly decide on the most suitable treatment path, resulting in improved outcomes, reduced hospital stays, and decreased healthcare costs.

Related Links:
Curetis GmbH

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.